# Corvus Pharmaceuticals stock is looking like a steal, Goldman Sachs says.

*biotech · news · 2026-04-17 · CNBC*

## Key points

- Goldman Sachs initiated coverage of Corvus Pharmaceuticals with a buy rating and $40 price target.
- Corvus is developing soquelitinib, a non-steroidal oral drug for atopic dermatitis treatment.
- Soquelitinib showed positive results in 75% of early-stage clinical trial participants as of January 2024.
- The global market for atopic dermatitis treatments is projected to reach over $24 billion by 2035.
- All seven analysts covering Corvus stock currently have a buy or strong buy rating.

**Companies:** Corvus Pharmaceuticals

[Read the full story on CNBC](https://www.cnbc.com/2026/04/17/this-stock-could-more-than-double-on-oral-eczema-treatment-goldman-sachs-says.html)

---

Canonical: https://newsio.io/n/db90ac76-f018-4d13-8e6e-c3677303f4e5/corvus-pharmaceuticals-stock-is-looking-like-a-steal-goldman-sachs-says-the-inve
Summarized by Newsio from CNBC. https://newsio.io/how-it-works